Should I Buy FG? FG 2026 Analysis

Should You Buy F&G Annuities & Life Inc (FG) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

28.380

1 Day change

3.09%

52 Week Range

47.760

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient entry: price is below the key pivot (28.8) with weak momentum and heavy put activity suggesting near-term caution.
Best near-term setup would be a reclaim of 28.8 and follow-through toward 29.7; without that, downside risk to ~27.9 support remains.
Earnings (QDEC 2025) on 2026-02-25 after hours is the next major catalyst; options are pricing elevated event risk.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend/momentum: MACD histogram is positive (0.169) but contracting, signaling bullish momentum is fading rather than strengthening.
RSI(6) ~43.96: neutral-to-soft (not oversold), so there’s no clear “bounce” signal.
Moving averages: converging, consistent with consolidation/chop rather than a clean uptrend.
Levels: Current ~28.21 sits below Pivot 28.8 (near-term bearish/neutral). Support S1 ~27.90 then S2 ~27.35; Resistance R1 ~29.70 then R2 ~30.26.
Pattern-based odds provided: modest positive skew over week/month (+5.15% next week, +3.41% next month) but not strong enough to override current weak tape.

Options Data

Bearish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Positioning/sentiment: Put open interest slightly exceeds calls (OI PCR 1.17) and today’s volume is heavily put-skewed (Volume PCR 3.56) → defensive/bearish near-term sentiment.
Activity: Today’s options volume is elevated vs 30-day average (~221%), indicating increased hedging/speculation into upcoming catalysts.
Volatility: IV percentile ~79.7 (elevated) with 30D IV ~45% vs HV ~41% → options priced rich, consistent with event risk (earnings upcoming).

Technical Summary

Sell

Buy

Positive Catalysts

- Potential demand tailwind: News highlights rising investor risk aversion and concern over long-term care costs, which can support interest in annuities/insurance solutions.
- Upcoming earnings (2026-02-25 AH): if results/guide confirm spread/capital resilience, the stock could re-rate back toward the ~$31 area.
- No notable insider selling pressure flagged (insiders neutral) and hedge fund activity neutral.

Neutral/Negative Catalysts

- Options market is leaning defensive (heavy put volume), suggesting traders are positioning for downside/volatility.
- Price is below the 28.8 pivot with fading MACD momentum—technically vulnerable to a retest of ~27.9 support.
- Earnings risk: with elevated IV and prior earnings volatility in profits, a miss or cautious outlook could pressure shares.
- Macro/industry headwinds noted by analyst: spread compression and tech spend can weigh on profitability.

Financial Performance

Latest quarter provided: 2025/Q3.
Revenue: $1.693B, up +16.44% YoY (solid top-line growth).
Profitability: Net income fell to $114M (down -1240% YoY) and EPS to $0.82 (down -1125% YoY), indicating a major profitability drawdown (likely from one-time items/reserves/mark-to-market impacts, but the data still signals earnings instability).
Overall: Growth in revenue is constructive, but the sharp earnings decline is a key overhang until clarity improves (next catalyst: QDEC 2025 earnings).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Latest update (2026-01-08): Barclays kept Equal Weight but cut price target to $31 from $35.
Street stance implied: “cautiously optimistic” on life insurers overall (capital strength/cash flow/consolidation positives), but still balancing headwinds (spread compression, technology spending).
Net take: Pros see resilience and consolidation benefits; cons focus on margin/earnings pressure—consistent with a neutral rating and reduced target.

2 Analyst Rating

Wall Street analysts forecast FG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FG is 32 USD with a low forecast of 31 USD and a high forecast of 33 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

2 Hold

0 Sell

Hold

Current: 27.530

Low

Averages

High

Current: 27.530

Low

Averages

High

Barclays

Alex Scott

Equal Weight

downgrade

$35 -> $31

AI Analysis

2026-01-08

Reason

Barclays

Alex Scott

Price Target

$35 -> $31

AI Analysis

2026-01-08

downgrade

Equal Weight

Reason

Barclays analyst Alex Scott lowered the firm's price target on F&G Annuities to $31 from $35 and keeps an Equal Weight rating on the shares. The firm is "cautiously optimistic" on life insurers heading into 2026, saying capital strength, cash flow, and consolidation offset headwinds like spread compression and technology spend. Barclays adjusted ratings and price targets as part of its 2026 outlook.

Barclays

Equal Weight

maintain

$37 -> $40

2025-08-07

Reason

Barclays

Price Target

$37 -> $40

2025-08-07

maintain

Equal Weight

Reason

Barclays raised the firm's price target on F&G Annuities to $40 from $37 and keeps an Equal Weight rating on the shares following the Q2 report. The core earnings power of the company improved this quarter, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for FG

Unlock Now

FG Should I Buy

FG Should I Buy

Should You Buy F&G Annuities & Life Inc (FG) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch